RLMD Stock Gets Stronger EPS Estimate from HC Wainwright

Relmada Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its Q4 2026 EPS estimate to a loss of $0.09 per share from a projected loss of $0.14. It also forecast a narrower FY2027 loss of $0.52 per share and a small profit of $0.01 in FY2030.
  • Relmada reported a quarterly loss of $0.12 per share, beating the consensus estimate of a $0.14 loss by $0.02. The stock was trading down 14.3% and opened at $3.61.
  • Analyst views are mixed: the consensus rating is “Moderate Buy” with a $12 average price target, while Weiss Ratings reaffirmed a “sell (d-)” rating.
  • MarketBeat previews the top five stocks to own by December 1st.

Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Stock analysts at HC Wainwright boosted their Q4 2026 EPS estimates for shares of Relmada Therapeutics in a research report issued on Friday, November 13th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.09) per share for the quarter, up from their previous estimate of ($0.14). The consensus estimate for Relmada Therapeutics' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Relmada Therapeutics' Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.45) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at $0.01 EPS.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Relmada Therapeutics in a research note on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Relmada Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $12.00.

View Our Latest Stock Analysis on Relmada Therapeutics

Relmada Therapeutics Trading Down 14.3%

NASDAQ RLMD opened at $3.61 on Tuesday. Relmada Therapeutics has a 12 month low of $3.07 and a 12 month high of $8.00. The company has a market capitalization of $385.08 million, a PE ratio of -5.01 and a beta of 0.62. The stock has a 50-day simple moving average of $3.75 and a 200 day simple moving average of $5.33.

Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02.

Institutional Trading of Relmada Therapeutics

A number of large investors have recently made changes to their positions in the company. Jupiter Topco LLC bought a new position in Relmada Therapeutics during the second quarter worth about $77,316,000. Janus Henderson Group PLC grew its stake in Relmada Therapeutics by 52.2% in the first quarter. Janus Henderson Group PLC now owns 11,063,862 shares of the company's stock valued at $76,892,000 after acquiring an additional 3,793,862 shares during the period. BlackRock Inc. bought a new stake in shares of Relmada Therapeutics in the second quarter worth about $51,393,000. Spruce Street Capital LP bought a new stake in shares of Relmada Therapeutics in the second quarter worth about $44,227,990. Finally, Orbimed Advisors LLC increased its holdings in shares of Relmada Therapeutics by 80.6% in the first quarter. Orbimed Advisors LLC now owns 4,715,864 shares of the company's stock worth $32,822,000 after acquiring an additional 2,105,264 shares in the last quarter. Institutional investors own 45.24% of the company's stock.

Insider Buying and Selling at Relmada Therapeutics

In other news, CFO Maged Shenouda purchased 120,200 shares of Relmada Therapeutics stock in a transaction dated Wednesday, September 9th. The shares were bought at an average cost of $4.20 per share, with a total value of $504,840.00. Following the completion of the transaction, the chief financial officer directly owned 920,200 shares in the company, valued at $3,864,840. This trade represents a 15.02% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.50% of the stock is currently owned by corporate insiders.

Latest Relmada Therapeutics News

Investors following RLMD have been watching these news items:

  • Positive Sentiment: HC Wainwright raised its EPS forecasts across several periods, including FY2027 to a loss of $0.52 per share from $0.61, FY2028 to a loss of $0.45 from $0.52, and FY2030 to a profit of $0.01 from a loss of $0.06. It also reduced projected losses for quarters from Q4 2026 through Q4 2027. The revisions suggest the analyst expects a narrower path of losses, though RLMD is still forecast to remain unprofitable for several years. MarketBeat Relmada Therapeutics
  • Positive Sentiment: Relmada appointed Dr. Jørn Skibsted Jakobsen as Chief Development Officer for Urology & Uro-Oncology. His experience leading the development program for an approved bladder-cancer therapy may strengthen execution as Relmada prepares the Phase 3 SPECTRUM program for NDV-01. The company cited encouraging Phase 2 results, but Phase 3 has not yet established the candidate’s efficacy or safety. Relmada appointment announcement

Relmada Therapeutics Company Profile

(Get Free Report)

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing investigational treatments for central nervous system disorders, with a focus on depression. The company's work centers on advancing drug candidates through clinical research; it does not have an approved commercial product. Its best-known candidate, REL-1017 (esmethadone), is an oral compound that acts on NMDA receptors. Relmada has studied it as an add-on treatment for adults with major depressive disorder who have not responded adequately to existing antidepressants.

See Also

Earnings History and Estimates for Relmada Therapeutics (NASDAQ:RLMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Relmada Therapeutics Right Now?

Before you consider Relmada Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relmada Therapeutics wasn't on the list.

While Relmada Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines